Caricamento...
Chemotherapeutic Agent Paclitaxel Mediates Priming of NLRP3 Inflammasome Activation
Paclitaxel is a chemotherapeutic drug commonly used to treat different types of cancer. In addition to its antitumor effect, paclitaxel is also known to promote Toll-like receptor (TLR) 4-dependent inflammatory responses, which may lower its chemotherapeutic efficacy. However, it remains unclear whe...
Salvato in:
| Pubblicato in: | Front Immunol |
|---|---|
| Autori principali: | , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Frontiers Media S.A.
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6532018/ https://ncbi.nlm.nih.gov/pubmed/31156650 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2019.01108 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|